Profile Details

Create Project

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Hire Dr. Karim E.

Belgium

Molecular biology, immunology, vaccinology, virology, gene- cell therapy, clinical and non-clinical research

Profile Summary

I hold a Ph.D. in Biological Sciences from the Université Libre de Bruxelles (ULB), Belgium, specializing in gene therapy against cancer. My expertise spans molecular biology, immunology, vaccinology, virology, and gene therapy. My professional journey is rich and varied, encompassing research, teaching, and scientific consulting. Scientific Research • Université Libre de Bruxelles (Belgium): Developed a tumor model to evaluate the in vivo anti-tumor activity of recombinant viral vectors. • R.E.D. Laboratories (Belgium): Developed in vitro models for screening therapeutics against chronic fatigue syndrome and multiple sclerosis. • University of Ghent (Belgium): Managed projects on in vivo models of inflammatory diseases and contributed to the development of a universal vaccine against the influenza A virus. • King Fahad Medical City (Saudi Arabia): Managed and supervised the Intramural Research Fund, established a biomedical research laboratory, and led the training and education department for research. • UCLouvain (Belgium): Scientific collaborator focused on developing new molecular diagnostic techniques. • EuroMed University of Fes - Health Department (Morocco): Professor-researcher, teaching molecular biology and immunology. Entrepreneurship • SciMed Services & Solutions (Belgium): Founder and Administrator. Scientific Consulting • Provided independent scientific consulting services for biotech companies, offering expertise in clinical studies, regulatory affairs, and European pharmaceutical legislation. In addition to my scientific and technical skills, I possess strong teaching abilities and remarkable adaptability. I have successfully taught molecular biology and immunology and am passionate about sharing knowledge and mentoring young researchers

Subject Matter Expertise

• ☆ Immunoassay
• ☆ Cell Biology
• ☆ Biotechnology & Bioengineering
• ☆ Nanobiotechnology
• ☆ Medical Devices
• ☆ Medical Device Development
• ☆ Medical Device Validation
• ☆ Medical Device Design
• ☆ Medical Device Regulatory Consulting
• ☆ European Medical Device Regulation (MDR)
• ☆ EU In vitro Diagnostic Regulation (IVDR) Compliance
• ☆ In vitro Diagnostics
• ☆ In vitro Diagnostic Design
• ☆ Point-of-Care Devices
• ☆ Biomarker Analysis
• ☆ Lab-on-a-Chip Devices
• ☆ Clinical Trials
• ☆ IRB Applications
• ☆ Clinical Trial Design
• ☆ Infectious Disease
• ☆ Viral Diseases
• ☆ Ebola
• ☆ West Nile Virus
• ☆ COVID-19
• ☆ Chikungunya
• ☆ Clinical Laboratory Science
• ☆ Regulatory Affairs
• ☆ Inflammation
• ☆ Medical Equipment & Supplies

Services

• Writing
• Research
• Consulting

Writing Clinical Trial Documentation, Medical Writing, Technical Writing

Research Scientific and Technical Research

Consulting Healthcare Consulting, Scientific and Technical Consulting, Regulatory Consulting

Work Experience

General Managar

SciMed Services &Solutions

August 2020 - Present

Education

Ph.D. Sciences

Université Libre de Bruxelles - Belgium

October 1994 - December 2001

Masters in Biotechnology

Université Libre de Bruxelles - Belgium

September 1992 - September 1994

Certifications

• Clinical Trials Expert

  CEFOCHIM

  June 2013 - Present

Publications

JOURNAL ARTICLE

Hamza, M., Alhujaily, M., Alosaimi, B., El Bakkouri, K., AlDughaim, M.S., Alonazi, M., Alanazi, M.A., Abbass, B., Alshehri, A., Al-Shouli, S.T., et al.(2023). Association between inflammatory cytokines/chemokines, clinical laboratory parameters, disease severity and in-hospital mortality in critical and mild COVID-19 patients without comorbidities or immune-mediated diseases . Journal of Immunoassay and Immunochemistry. 44. (1). p. 13-30.

Karim El Bakkouri(2021). Hydroxychloroquine (HCQ): real treatment or false hope? . International Journal of Antimicrobial Agents. 57. (1). p. 106170. Elsevier {BV}

El Bakkouri, K.(2021). Hydroxychloroquine (HCQ): real treatment or false hope? . International Journal of Antimicrobial Agents. 57. (1).

(2020). Antigenic Drift of Hemagglutinin and Neuraminidase in seasonal H1N1 influenza Viruses from Saudi Arabia in 2014‐2015 . Journal of Medical Virology.

Alothaid, H., Aldughaim, M.S.K., El Bakkouri, K., AlMashhadi, S., Al-Qahtani, A.A.(2020). Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID19 progression: a review of potential targets for diagnosis and treatment . Channels. 14. (1). p. 403-412.

Eliasson, D.G., Omokanye, A., Schön, K., Wenzel, U.A., Bernasconi, V., Bemark, M., Kolpe, A., El Bakkouri, K., Ysenbaert, T., Deng, L., et al.(2018). M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection . Mucosal Immunology. 11. (1). p. 273-289.

Van den Hoecke, S., Ehrhardt, K., Kolpe, A., El Bakkouri, K., Deng, L., Grootaert, H., Schoonooghe, S., Smet, A., Bentahir, M., Roose, K., et al.(2017). Hierarchical and redundant roles of activating FcγRs in protection against influenza disease by M2e-specific IgG1 and IgG2a antibodies . Journal of Virology. 91. (7).

Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al.(2016). Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea . PLoS Medicine. 13. (3).

El Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., Van Rooijen, N., Verbeek, S., Fiers, W., Saelens, X.(2011). Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection . Journal of Immunology. 186. (2). p. 1022-1031.

Eliasson, D.G., Helgeby, A., Schön, K., Nygren, C., El-Bakkouri, K., Fiers, W., Saelens, X., Lövgren, K.B., Nyström, I., Lycke, N.Y.(2011). A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus . Vaccine. 29. (23). p. 3951-3961.

Müller, K.H., Kainov, D.E., El Bakkouri, K., Saelens, X., De Brabander, J.K., Kittel, C., Samm, E., Muller, C.P.(2011). The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections . British Journal of Pharmacology. 164. (2). p. 344-357.

Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X(2009). M2e-based universal influenza A vaccine . Vaccine.

Fiers, W., De Filette, M., Bakkouri, K.E., Schepens, B., Roose, K., Schotsaert, M., Birkett, A., Saelens, X.(2009). M2e-based universal influenza A vaccine . Vaccine. 27. (45). p. 6280-6283.

Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N(2008). CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine . Vaccine.

Eliasson, D.G., Bakkouri, K.E., Schön, K., Ramne, A., Festjens, E., Löwenadler, B., Fiers, W., Saelens, X., Lycke, N.(2008). CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine . Vaccine. 26. (9). p. 1243-1252.

Wullaert, A., Verstrepen, L., Van Huffel, S., Adib-Conquy, M., Cornelis, S., Kreike, M., Haegman, M., El Bakkouri, K., Sanders, M., Verhelst, K., et al.(2007). LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-κB activation . Journal of Biological Chemistry. 282. (1). p. 81-90.

Karim El Bakkouri, Andy Wullaert, Lynn Verstrepen, Sofie Van Huffel, Minou Adib-Conquy, Sigrid Cornelis, Marja Kreike, Mira Haegman, Matthew Sanders, Kelly Verhelst, et al.(2006). LIND/ABIN-3 Is a Novel Lipopolysaccharide-inducible Inhibitor of NF-κB Activation . Journal of Biological Chemistry. 282. (1). p. 81--90. American Society for Biochemistry {\&} Molecular Biology ({ASBMB})

Wullaert A, Wielockx B, Van Huffel S, Bogaert V, De Geest B, Papeleu P, Schotte P, El Bakkouri K, Heyninck K, Libert C, et al.(2005). Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality . Hepatology (Baltimore, Md.).

Karim El Bakkouri, Andy Wullaert, Mira Haegman, Karen Heyninck, Rudi Beyaert(2005). Adenoviral Gene Transfer of the NF-κB Inhibitory Protein ABIN-1 Decreases Allergic Airway Inflammation in a Murine Asthma Model . Journal of Biological Chemistry. 280. (18). p. 17938--17944. American Society for Biochemistry {\&} Molecular Biology ({ASBMB})

El Bakkouri, K., Servais, C., Clément, N., Cheong, S.C., Franssen, J.-D., Velu, T., Brandenburger, A.(2005). In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA . Journal of Gene Medicine. 7. (2). p. 189-197.

Wullaert, A., Wielockx, B., Van Huffel, S., Bogaert, V., De Geest, B., Papeleu, P., Schotte, P., Bakkouri, K.E., Heyninck, K., Libert, C., et al.(2005). Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine- induced acute liver failure and lethality . Hepatology. 42. (2). p. 381-389.

Frémont, M., El Bakkouri, K., Vaeyens, F., Herst, C.V., De Meirleir, K., Englebienne, P.(2005). 2′,5′-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome . Experimental and Molecular Pathology. 78. (3). p. 239-246.

El Bakkouri, K., Wullaert, A., Haegman, M., Heyninck, K., Beyaert, R.(2005). Adenoviral gene transfer of the NF-κB inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model . Journal of Biological Chemistry. 280. (18). p. 17938-17944.

Clément, N., Avalosse, B., El Bakkouri, K., Velu, T., Brandenburger, A.(2001). Cloning and sequencing of defective particles derived from the autonomous parvovirus minute virus of mice for the construction of vectors with minimal cis-acting sequences . Journal of Virology. 75. (3). p. 1284-1293.

Karim El Bakkouri, Annick Brandenburger, Elise Coessens, Thierry Velu(1999). Influence of Sequence and Size of DNA on Packaging Efficiency of Parvovirus MVM-Based Vectors . Human Gene Therapy. 10. (7). p. 1229--1238. Mary Ann Liebert Inc

Brandenburger, A., Coessens, E., Bakkouri, K.E.L., Velu, T.(1999). Influence of sequence and size of DNA on packaging efficiency of parvovirus MVM-based vectors . Human Gene Therapy. 10. (7). p. 1229-1238.

El Bakkouri, K., Clement, N., Velu, T., Brandenburger, A.(1999). Amplification of MVM(p) vectors through serial infection of a new packaging cell line . Tumor Targeting. 4. (4). p. 210-217.

OTHER

Karim El Bakkouri, Kenny Roose, Michael Schotsaert, Bert Schepens, Walter Fiers, Xavier Saelens(2012). Cutting Edge Approaches Toward Novel and Cross-Protective Influenza Vaccines . Development of Novel Vaccines. p. 205--232. Springer Vienna

Karim El Bakkouri, Bernard Lebleu, C Vincent Herst, Karen De Smet, Simon Roelens, Edith Demettre, Marc Frémont, Anne D’Haese, Lionel Bastide, Patrick Englebienne(2002). Ribonuclease L . Chronic Fatigue Syndrome. p. 17--54. {CRC} Press

BOOK

Roose, K., Schotsaert, M., El Bakkouri, K., Schepens, B., Fiers, W., Saelens, X.(2012). Cutting edge approaches toward novel and cross-protective influenza vaccines . Development of Novel Vaccines: Skills, Knowledge and Translational Technologies. p. 205-232.